Moderna, Inc. (MRNA)
| Market Cap | 10.78B |
| Revenue (ttm) | 3.18B |
| Net Income (ttm) | -3.36B |
| Shares Out | 386.74M |
| EPS (ttm) | -8.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,003,019 |
| Open | 27.80 |
| Previous Close | 27.61 |
| Day's Range | 27.18 - 28.52 |
| 52-Week Range | 23.15 - 170.47 |
| Beta | 2.00 |
| Analysts | Hold |
| Price Target | 51.94 (+86.37%) |
| Earnings Date | May 1, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $51.94, which is an increase of 86.37% from the latest price.
News
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combinatio...
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive ...
Moderna Posts Loss, Citing Seasonality of Respiratory Business
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Moderna beats Wall Street estimates for first-quarter profit and sales
Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine...
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of...
Moderna Earnings Arrive During a Tough Time for the Stock
Moderna shares are down more than 30% this year, and around 75% over the past 12 months.
33 Stocks That Could Rally 50% or More This Year
Analysts say these S&P 500 stocks have at least 50% price upside over the next year or so.
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report ...
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ...
Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter
Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as Ireland.
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Resignation of FDA Vaccine Official
Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade policy remained in focus.
S&P 500 recoups losses, Dow rises as volatile March ends; Newsmax surges, Moderna tanks
Investors were nervous about US President Donald Trump's tariff plans, which caused the S&P 500 to fall on Monday and enter correction territory. However, the index recovered its losses from earlier ...
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345),...
Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)
Moderna (NASDAQ:MRNA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ET Company Participants Rose Loughlin - EVP of Research Lavina Talukdar - SVP, Head of IR Conference Cal...
3 CEOs Just Spent Millions Buying Their Beaten-Down Stock
The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 after a tough 2024.
Moderna: Insider Buy Signal
Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation. Moderna cut revenue guidance f...
S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism
Major U.S. equities indexes fluctuated on Wednesday before gaining momentum in the afternoon to close the session higher.